RANKL Signaling and ErbB Receptors in Breast Carcinogenesis

详细信息    查看全文

• 作者：Ilianna Zoi¹ ; ² ; Michalis V. Karamouzis¹ ; ² ; ^{mkaramouz@med.uoa.gr" class="auth_mail" title="E-mail the corresponding author} ; Christos Adamopoulos¹ ; Athanasios G. Papavassiliou¹ ; ^{papavas@med.uoa.gr" class="auth_mail" title="E-mail the corresponding author}
• 关键词：breast cancer ; ErbB ; ErbB2 ; NF-κB ; RANK
• 刊名：Trends in Molecular Medicine
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：22
• 期：10
• 页码：839-850
• 全文大小：2754 K

文摘

ErbB family members, ErbB1/EGFR/HER-1, ErbB2/HER-2, ErbB3/HER-3 and ErbB4/HER-4, have been implicated in breast cancer (BC) tumorigenicity. Recently, crucial roles for RANK/RANKL signaling in addition to key downstream factor NF-κB have been demonstrated in mammary tumorigenesis. Here, we present the hypothesis of a novel association between ErbB and RANK pathways in promoting BC. The proposed model alludes to the cross-talk that might occur between RANK and ErbB receptors. This interplay might regulate RANK signaling and consequently, modulate carcinogenesis, mainly in ErbB2 over-expressing BC cells. Thus, we highlight the significance of the RANK/RANKL axis as a putative therapeutic target in this malignancy, and furthermore, suggest that the combination of ErbB and RANK/RANKL inhibitors may have therapeutic benefit for certain BC patients.